The demonstration of cardiorenal benefits with SGLT2i in clinical trials both for participants with CKD and type 2 diabetes and for those without [23,24,25] and the updated 2022 KDIGO guidelines recommending SGLT2i as first-line therapy for patients with CKD and type 2 diabetes regardless of glycemic control [6] have likely driven a shift toward their broader use for preventive cardiorenal protection and earlier implementation for patients with type 2 diabetes
Wei J, Yang B, Wang R, et al
In contrast with other GLP-1 agonists, maternal exposure to exendin-4 resulted in an increase in pre-weaning fetal growth in one study ( The fetal effects of maternal exposure to GLP-1 agonists were marked
In this comprehensive guide, we will explore the core facts about this transformative medication
Whether ipamorelin specifically causes premature epiphyseal closure in humans is unknown
This differs from providers that automatically charge monthly